Nav: Home

Major drug initiatives are best way to curb threat from parasites

January 25, 2017

Large-scale programmes to treat a life-threatening disease could improve the health of millions despite concerns about their long-term effects, a study suggests.

The research offers fresh insights into the effectiveness of major initiatives set up to treat bilharzia -- also known as snail fever. The infection kills an estimated 280,000 people each year.

The number of people treated for bilharzia with a commonly used drug -- called praziquantel -- has increased significantly in recent years through mass drug administration, or MDA, programmes.

These programmes treat whole populations of people in at-risk communities, regardless of whether they are infected or not, but little is known about how effective they will be in the long term, researchers say.

Scientists are calling for close monitoring of praziquantel MDA programmes over coming decades to ensure the treatments continue to be effective against bilharzia. Failure to do so could have major implications for the severity and spread of the disease, the team from the University of Edinburgh says.

Bilharzia infects around 240 million people, mostly in sub-Saharan Africa. A further 600 million people worldwide are at risk of infection, the team says. It is the second most prevalent parasitic disease after malaria.

The disease, which is carried by freshwater snails infected with parasitic worms, can cause poor physical and cognitive development in children, and serious illness in people of all ages.

Praziquantel is a highly effective treatment for snail fever, but its long-term effects are largely unknown, researchers say.

Since being approved for use in the 1980s, praziquantel has become the main treatment for bilharzia. The drug works with the body's immune system to kill parasitic worms - known as schistosomes -- and boosts people's natural immunity to them, helping to reduce re-infection.

However, it is not known how long people remain resistant to re-infection once praziquantel treatments have ended, researchers say. Faced with entire populations of people treated with praziquantel, parasites could also potentially develop resistance to the drug, they add.

According to the World Health Organization, more than 62 million people were treated for bilharzia through praziquantel MDA programmes in 2014. Efforts to extend these initiatives to treat all those at risk of infection are under way.

Additional control strategies are also needed to help prevent future outbreaks of the disease, the team says. In the absence of such measures -- including improved sanitation, snail control and access to safe water - cases of bilharzia could occur years after MDA programmes end.

The study is published in the journal Lancet Infectious Diseases. The work was carried out in collaboration with the Schistosomiasis Control Initiative at Imperial College London.

Dr Francisca Mutapi, of the University of Edinburgh's School of Biological Sciences, who led the study, said: "For the first time, we are approaching a point where most people affected by bilharzia will receive treatment at least once during their lifetime. MDA programmes are a welcome development but, in planning for the future, we need to know more about their complex effects on the affected populations - both human and parasite."

University of Edinburgh

Related Infection Articles:

Sensing infection, suppressing regeneration
UIC researchers describe an enzyme that blocks the ability of blood vessel cells to self-heal.
Boost to lung immunity following infection
The strength of the immune system in response to respiratory infections is constantly changing, depending on the history of previous, unrelated infections, according to new research from the Crick.
Is infection after surgery associated with increased long-term risk of infection, death?
Whether experiencing an infection within the first 30 days after surgery is associated with an increased risk of another infection and death within one year was the focus of this observational study that included about 660,000 veterans who underwent major surgery.
Revealed: How E. coli knows how to cause the worst possible infection
The discovery could one day let doctors prevent the infection by allowing E. coli to pass harmlessly through the body.
UK study shows most patients with suspected urinary tract infection and treated with antibiotics actually lack evidence of this infection
New research presented at this week's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam, Netherlands (April 13-16, 2019) shows that only one third of patients that enter the emergency department with suspected urinary tract infection (UTI) actually have evidence of this infection, yet almost all are treated with antibiotics, unnecessarily driving the emergence of antimicrobial resistance.
Bacteria in urine doesn't always indicate infection
Doctors should think carefully before testing patients for a urinary tract infection (UTI) to avoid over-diagnosis and unnecessary antibiotic treatment, according to updated asymptomatic bacteriuria (ASB) guidelines released by the Infectious Diseases Society of America (IDSA) and published in Clinical Infectious Diseases.
Subsidies for infection control to healthcare institutions help reduce infection levels
Researchers compared three types of infection control subsidies and found that under a limited budget, a dollar-for-dollar matching subsidy, in which policymakers match hospital spending for infection control measures, was the most effective at reducing the number of hospital-acquired infections.
Dengue virus infection may cause severe outcomes following Zika virus infection during pregnancy
This study is the first to report a possible mechanism for the enhancement of Zika virus progression during pregnancy in an animal model.
How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.
The medicine of the future against infection and inflammation?
Researchers at Lund University in Sweden, have in collaboration with colleagues in Copenhagen and Singapore, mapped how the body's own peptides act to reduce infection and inflammation by deactivating the toxic substances formed in the process.
More Infection News and Infection Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Making Amends
What makes a true apology? What does it mean to make amends for past mistakes? This hour, TED speakers explore how repairing the wrongs of the past is the first step toward healing for the future. Guests include historian and preservationist Brent Leggs, law professor Martha Minow, librarian Dawn Wacek, and playwright V (formerly Eve Ensler).
Now Playing: Science for the People

#566 Is Your Gut Leaking?
This week we're busting the human gut wide open with Dr. Alessio Fasano from the Center for Celiac Research and Treatment at Massachusetts General Hospital. Join host Anika Hazra for our discussion separating fact from fiction on the controversial topic of leaky gut syndrome. We cover everything from what causes a leaky gut to interpreting the results of a gut microbiome test! Related links: Center for Celiac Research and Treatment website and their YouTube channel
Now Playing: Radiolab

The Flag and the Fury
How do you actually make change in the world? For 126 years, Mississippi has had the Confederate battle flag on their state flag, and they were the last state in the nation where that emblem remained "officially" flying.  A few days ago, that flag came down. A few days before that, it coming down would have seemed impossible. We dive into the story behind this de-flagging: a journey involving a clash of histories, designs, families, and even cheerleading. This show is a collaboration with OSM Audio. Kiese Laymon's memoir Heavy is here. And the Hospitality Flag webpage is here.